linjc16/ctgov huggingface dataset:
Effectiveness and Safety of Duloxetine in Women Experiencing Urinary Leakage Due to Physical Stress and Urge.

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate the effectiveness of duloxetine in reducing urinary incontinence(leakage of urine)occurrences in women due to physical stress and leakage that occurs during a strong need(urge) to urinate.

Official Title
-----------------
Efficacy and Safety of Duloxetine Compared With Placebo in Women With Symptoms of Mixed Urinary Incontinence.

Conditions
-----------------
Urinary Incontinence, Stress

Intervention / Treatment
-----------------
* Drug: duloxetine
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: female outpatients greater than or equal to 18 years of age. experience episodes of urinary incontinence based on diagnostic criteria of at least 4 episodes a week with symptoms for a minimum of three months prior to start of study. have an educational level and degree of understanding English. are free of urinary tract infections. have a discreet episodes of incontinence(i.e. dry between episodes and do not continuously leak.) Exclusion Criteria: have received treatment for incontinence within the last 5 years. suffer from severe constipation. currently nursing or breast feeding. any nervous system disease that would affect normal urinary function. any extension of internal organs beyond the vaginal opening.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: duloxetine|nan|
|Drug: placebo|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The study purpose is to assess the efficacy of duloxetine 40 mg BID for up to 8 weeks in women with mixed urinary incontinence(MUI) compared with placebo as measured by: the change in total incontinence episode frequency(IEF) from baseline to endpoint. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Additional assessments of incontinence episode frequency using various standardized instruments will be performed. |  |  | 
| To monitor the safety of duloxetine based on clinical laboratory values and the occurrence of treatment-emergent adverse events. |  |  |
Thin-EBUS in Ex-vivo Human Lungs

Study Overview
=================
Brief Summary
-----------------
This study will determine the feasibility of the novel thin convex probe endobronchial ultrasound (TCP-EBUS) in human resected lobes. The primary end point is to clarify the feasibility of using the thin convex probe EBUS scope to visualize lung tumors from an intra-bronchial view. The secondary objective is to evaluate the insertion ability, operability, endoscopic image and ultrasound image compared to that of the convex probe EBUS.

Official Title
-----------------
Feasibility of the Thin Convex Probe Endobronchial Ultrasound (TCP-EBUS) System for Lymph Node Staging

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Device: Thin Convex Probe Endobronchial Ultrasound (TCP-EBUS)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patients scheduled for lobectomy or anatomical segmental resection for malignant lung tumors. 18 years of age or older Exclusion Criteria: Any patients with inability to give informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: No Intervention<br> | Device: Thin Convex Probe Endobronchial Ultrasound (TCP-EBUS)<br>* Patients scheduled for a lobectomy will be recruited to this study and approached for informed consent. At the time of surgery, once the lobe has been removed, the TCP-EBUS will be inserted through a bronchial stamp for brief operability evaluations and image acquisition. Once this data has been captured standard of care will continue.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To clarify the feasibility of using the thin convex probe EBUS scope to visualize lung tumors from an intra bronchial view. | The TCP-EBUS bronchoscope will be inserted through the endotracheal tube for visualization of lobar, segmental and sub segmental bronchi. | Within an hour of resection. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lobectomy
Using Online Videos to Supplement Emergency Department Discharge Instructions

Study Overview
=================
Brief Summary
-----------------
This project will evaluate the effectiveness of 38 videos of discharge instructions for patients seen in, and discharged from, the emergency department (ED). The investigators will (1) assess how many ED patients chose view the website, and (2) interview patients who viewed a video, as well as those who didn't view a video (and therefore received standard care), to determine whether patients who viewed a video understood their diagnoses and discharge instructions better.

Official Title
-----------------
Speak Fast, Use Jargon, and Don't Repeat Yourself: Using Online Videos to Supplement Emergency Department Discharge Instructions

Conditions
-----------------
Emergency Department Discharge Instructions, Instruction Videos

Intervention / Treatment
-----------------
* Other: Video of ED discharge instructions for patient's ED discharge diagnosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 16, or < 16 and accompanied by a legal guardian Has one of 38 ED discharge diagnoses Fluent in English, or caregiver fluent Has access to a computer, with internet access, in the next 4 days Has access to a telephone Exclusion Criteria: Age < 16 when unaccompanied by a legal guardian Decreased level of consciousness at ED discharge (eg palliative patient)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Video of ED Discharge Instructions<br> | Other: Video of ED discharge instructions for patient's ED discharge diagnosis<br>* Link provided for a website of 38 ED discharge instruction videos, based on ED discharge diagnosis; patients in study group encouraged to view it upon returning home. Three key questions asked by RA 1 to 5 days later, via phone call, and answers scored.<br>|
| No Intervention: Control (usual standard of care)<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Score out of 3 points on 3 key questions | 3 key questions have been created for each of 38 ED discharge diagnosis. Scores will be compared between intervention group and control group. | 1 to 5 days after ED visit | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Quality rating of video of discharge instructions, Likert scale 1 to 5 | Rating by study arm (who viewed a video) as to how helpful the video was in helping them (1) understand their discharge instructions, and (2) overall usefulness of the video. | 1 to 5 days after ED discharge |
An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation

Study Overview
=================
Brief Summary
-----------------
Open-label comparison of standard 12-week regimen of varenicline with standard 10-week regimen of transdermal nicotine patch for smoking cessation.

Official Title
-----------------
An Open-Label, Multicenter Study With Follow-Up Evaluating the Safety and Efficacy of Varenicline Tartrate in Comparison to Transdermal Nicotine Patch for Smoking Cessation

Conditions
-----------------
Smoking Cessation

Intervention / Treatment
-----------------
* Drug: varenicline (CP-526,555)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects must have smoked an average of at least 15 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year. Exclusion Criteria: Subjects with clinically significant cardiovascular disease in the past 6 months.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: varenicline (CP-526,555)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Continuous abstinence for the last 4 weeks of varenicline and NRT (Nicotine Replacement Therapy) treatment period |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Continuous abstinence last 4 weeks of treatment through Weeks 24 and 52 |  |  | 
| 7-day point prevalence of abstinence: end of treatment, Weeks 24 and 52 |  |  | 
| 4-week Point Prevalence of abstinence at Week 52 |  |  | 
| Long-Term Quit Rate at Weeks 24 and 52 |  |  | 
| Minnesota Nicotine Withdrawal Scale |  |  | 
| Smoking Effects Inventory |  |  |
Safety Study of Clinical Cell Transplant Therapy Using Hearticellgram-AMI for Patients With Acute Myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the safety of the previously conducted clinical trial cell transplant therapy using Hearticellgram-AMI for patients with acute myocardial infarction. This is a follow-up observational study and targeting the subjects who participated in the previously conducted clinical trial.

Detailed Description
-----------------
The safety evaluation in this clinical trial is performed with variables, such as occurrence and severity of adverse events, clinical laboratory tests, vital signs, physical examination, cardiac events, and cancer.

Official Title
-----------------
A Follow-up Observational Study of Safety of Clinical Trial Conducted With Cell Transplant Therapy Using Hearticellgram-AMI for Patients With Acute Myocardial Infarction

Conditions
-----------------
Acute Myocardial Infarction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have elapsed for more than 2 years after onset of acute myocardial infarction among the patients who had received cell transplant therapy or drug treatment at least once in test and control group on the previously conducted clinical trial. Subjects agreed to participate in this follow-up study and signed the consent form. Exclusion Criteria: N/A

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Prevalence of Molar Incisor Hypominerlization (MIH) Among a Group of Egyptian Children

Study Overview
=================
Brief Summary
-----------------
To determine the Prevalence of MIH in a group of Egyptian children attending the Pediatric Dentistry and Dental Public Health Department, Faculty of Dentistry, Cairo University.

Detailed Description
-----------------
One single operator, Master degree student in the department of Pediatric Dentistry and Dental public health, Faculty of Dentistry, Cairo University will assess incidence of molar incisor hypomineralization for all the patients who will be included in the study sample. The survey will involve a structured questionnaire which will be followed by clinical examination to assess the presence / absence of molar incisor hypomineralization and its severity based on EAPD criteria

Official Title
-----------------
Prevalence of Molar Incisor Hypominerlization (MIH) Among a Group of Egyptian Children: A Cross Sectional Study

Conditions
-----------------
Molar Incisor Hypomineralization

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Children age from eight to twelve years. Medically free. Singed informed consent. Both sexes are included Parent and children cooperation. Exclusion Criteria: Children with (amelogenesis imperfecta, tetracycline tooth stains, extensive destruction due to caries, or have restoration or crown and fluorosis). Children with orthodontic bands on the first permanent molars preventing adequate clinical examination.

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence of molar incisor hypomineralization among a group of Egyptian Children | prevalence of molar incisor hypomineralization measured by clinical examination | baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relationship of MIH with dental caries | Relationship of MIH with dental caries measured by caries index | baseline |
Distance Learning and Neck Problems During Pandemic Period

Study Overview
=================
Brief Summary
-----------------
For people who use computers a lot, Work-related musculoskeletal disorders of the neck are a common problem . It is generally agreed that the etiology of work-related neck disorders is multidimensional which is associated with, and influenced by, a complex array of individual, physical and psychosocial factors.

Detailed Description
-----------------
Academic staff work involves diverse activities, both in and out of lecture-rooms, designing course curricula, developing lecture and tutorial plans and materials, providing students with information in an interesting and understandable manner, setting questions, and marking examinations .These activities usually involve long periods of sitting and standing, placing a physical demand on the lower back, cervical spine and the vertebral column in general, thus contributing to neck and shoulder discomfort .Lecturers use computers extensively and are thus exposed to many of the same risk factors to which 'office workers' are exposed. Using a computer is associated with poor neck posture most often in a forward head position, which is thought to be one of the most common causes of neck, head and shoulder tension and pain . Neck pain is costly in terms of treatment, individual suffering, and time lost due to work absenteeism . Effective performance of academic staff of the university is very important as the key factors to a successful day to day running of any university system .

Official Title
-----------------
Distance Learning and Neck Disability Among Academic Staff During COVID-19 Period

Conditions
-----------------
Neck Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least one year of work experience in the current position as academic stuff. Exclusion Criteria: Spinal deformities or specific medical condition affecting the cervical spine (e.g., ankylosing spondylitis, radiculopathy, tumors, infection and disc prolapse) History of spinal surgery Previous head or neck trauma

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neck disability index | It is designed to provide information as to how neck pain affects a person's ability to manage in everyday life | 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain severity | Pain severity will be assessed using an 11- point numerical rating scale , where zero = no pain, 10 = unbearable pain. Each participant will rate the pain perceived along the scale at the point which refers to pain severity. | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Online Learning, Neck Pain, COVID-19
Myo-inositol as Pretreatment in Hyperandrogenic PCOS Patients

Study Overview
=================
Brief Summary
-----------------
A randomized controlled trial to evaluate whether pretreatment with myo-inositol can lower testosterone levels and improve clinical outcomes in hyperandrogenic PCOS patients undergoing ART

Official Title
-----------------
Pretreatment With Myo-inositol in Hyperandrogenic PCOS Patients Undergoing ART: a Randomized Controlled Trial

Conditions
-----------------
PCOS, Female Infertility

Intervention / Treatment
-----------------
* Drug: Myo-inositol
* Drug: Folic Acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women aged 18-40 years PCOS phenotypes A, B and C Signed informed consent Exclusion Criteria: Other relevant endocrine disorders Contraindications to the use of gonadotropins Endometriosis grade 3-4 BMI > 35

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Randomized controlled trial
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Myo-inositol<br>Pretreatment with Gynositol (Myo-Inositol 4mg + Folic Acid 0.4mg) daily during 12 weeks before start of ART (Assisted Reproductive Technology) | Drug: Myo-inositol<br>* Myo-inositol and Folic acid daily<br>|
| Other: Folic acid<br>Folic acid 0.4 mg daily during 12 weeks before start of ART | Drug: Folic Acid<br>* Folic Acid daily<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum testosterone level after 12 weeks of administration of Myo-Inositol |  | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Androstenedione and SHBG (Sex Hormone Binding Globulin) plasma levels after 12 weeks of administration of Myo-Inositol |  | 2 years | 
| Number of mature oocytes |  | 2 years | 
| Embryo quality | Day 3 embryos will be classified as transferable or cryopreservable/ 'good-quality embryos' (GQE) according to the criteria described by Van Landuyt et al. (2013). Blastocysts will be categorized according to Gardner et al. (1998) and Gardner and Schoolcraft (1999). | 2 years | 
| Implantation rate (%) |  | 2 years | 
| Clinical pregnancy rate (%) |  | 2 years | 
| Live birth rate in fresh cycle |  | 2 years | 
| Cumulative live birth rate after 1 cycle |  | 2 years | 
| Ovarian Hyperstimulation Syndrome rate |  | 2 years | 
| Consumption of gonadotrophins | measurement in IU | 2 years | 
| Stimulation days | measurement in days | 2 years |
The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in Human

Study Overview
=================
Brief Summary
-----------------
This is an observation study to investigate the molecular mechanism of NKG2C+NK cell expansion after HCMV infection

Detailed Description
-----------------
According to the changes of molecular and gene expression in NK cells at different time points after infection, we want to find out the mechanism by which HCMV promotes the expansion of NKG2C + NK cells.

Official Title
-----------------
The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in Human

Conditions
-----------------
Acute Leukemia, CMV Viremia, Hematopoietic Stem Cell Transplantation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: AML or MDS or CML or ALL undergoing haploidentical stem cells transplantation No severe organ dysfunction or failure Subjects must be capable of, and willing to provide written informed consent to participate in the study. Subjects unable to provide written informed consent by themselves may be consented through their legal representative. Exclusion Criteria: Participation in another industry-sponsored clinical study where treatment for CMV is already specified by the study protocol. Patients received other adoptive immunotherapy such as donor lymphocyte infusion (DLI), Epstein-Barr virus (EBV)-specific T cells and so on.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| CMV viremia | CMV-DNA>1.0x10^3 cpies/mL | 2 moths post-transplantation |